HIND Stock Rallies 70% Pre-Market Today – Find Out Why
admin | September 17, 2025 10:22 PM CST
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said.
Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrop has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied by over 60% in pre-market trading on Wednesday.
Add Asianet Newsable as a Preferred Source
Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome.
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company stated.
Get updates to this developing story <directly on Stocktwits.<
READ NEXT
-
Weight Loss: R. Madhavan said simple and inexpensive solutions to lose weight in just 21 days, learn how
-
Samsung released Android 16 based One UI 8, Galaxy S25 series rollout
-
Samsung Galaxy S26 ULTRA’s increased craze, leaked before launch! Changes in design
-
Thinking About a New SUV? The Hyundai Exter Has Some Solid Offers This September:
-
Ashes 2025-26: Marnas Labushen said, which Indian veteran is taking inspiration! , Read
